GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Cyclically Adjusted PB Ratio

Jazz Pharmaceuticals (STU:J7Z) Cyclically Adjusted PB Ratio : 2.08 (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-22), Jazz Pharmaceuticals's current share price is €98.84. Jazz Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €47.56. Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.08.

The historical rank and industry rank for Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:J7Z' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.05   Med: 5.76   Max: 27.84
Current: 2.05

During the past years, Jazz Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 27.84. The lowest was 2.05. And the median was 5.76.

STU:J7Z's Cyclically Adjusted PB Ratio is ranked worse than
54.69% of 651 companies
in the Biotechnology industry
Industry Median: 1.71 vs STU:J7Z: 2.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €53.956. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €47.56 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.67 5.28 3.23 3.46 2.40

Jazz Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 2.52 2.57 2.40 2.31

Competitive Comparison of Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=98.84/47.56
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Jazz Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=53.956/120.9901*120.9901
=53.956

Current CPI (Mar. 2024) = 120.9901.

Jazz Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 15.640 100.773 18.778
201409 17.197 100.474 20.709
201412 18.337 99.576 22.280
201503 19.761 99.975 23.915
201506 21.055 100.573 25.329
201509 22.652 100.274 27.332
201512 23.939 99.676 29.058
201603 23.862 99.676 28.964
201606 24.903 101.072 29.811
201609 25.528 100.274 30.802
201612 29.751 99.676 36.113
201703 30.923 100.374 37.274
201706 32.599 100.673 39.178
201709 34.558 100.474 41.615
201712 38.275 100.075 46.274
201803 37.672 100.573 45.320
201806 40.747 101.072 48.777
201809 43.010 101.371 51.334
201812 42.150 100.773 50.606
201903 42.466 101.670 50.536
201906 46.628 102.168 55.218
201909 48.984 102.268 57.952
201912 49.873 102.068 59.119
202003 45.905 102.367 54.256
202006 50.309 101.769 59.811
202009 51.577 101.072 61.742
202012 53.556 101.072 64.111
202103 56.091 102.367 66.295
202106 56.110 103.364 65.678
202109 54.541 104.859 62.931
202112 56.937 106.653 64.591
202203 52.640 109.245 58.299
202206 48.352 112.779 51.872
202209 44.087 113.504 46.995
202212 46.081 115.436 48.298
202303 48.681 117.609 50.080
202306 51.330 119.662 51.900
202309 51.943 120.749 52.047
202312 55.045 120.749 55.155
202403 53.956 120.990 53.956

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jazz Pharmaceuticals  (STU:J7Z) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (STU:J7Z) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (STU:J7Z) Headlines

No Headlines